Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report)’s stock price fell 4.5% during trading on Tuesday . The company traded as low as C$8.48 and last traded at C$8.48. 446 shares traded hands during trading, a decline of 51% from the average session volume of 918 shares. The stock had previously closed at C$8.88.
Neuren Pharmaceuticals Trading Down 4.5%
The stock’s fifty day moving average price is C$8.77 and its 200 day moving average price is C$10.14.
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.
The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.
Featured Stories
- Five stocks we like better than Neuren Pharmaceuticals
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
